Clinical Research Directory

Pharmacogenetics of Leflunomide in the Management of Rheumatoid Arthritis

Sponsor: Foundation University Islamabad

Summary

1. Patients taking leflunomide as the only disease-modifying anti-rheumatic drug (DMARD) will be recruited after consent. 2. Blood sample for DNA extraction will be taken The patient will be followed up till two visits 3 months apart, and efficacy and toxicity will be checked using DAS28, ultrasonography, and blood tests for ESR, CRP, anti-CCP, liver function tests, etc. The data form for toxicity will be filled. 3. DNA will be extracted in the laboratory, and SNP will be identified. 4. The efficacy and toxicity data will be studied against the SNPs found 5. An algorithm will be constructed for Pakistani RA patients taking leflunomide.

Official title: Pharmacogenetics of Leflunomide in the RA Management

Key Details

Conditions

Interventions

Locations (2)